ING-013Medication Research Profile · Prescription Only
Weight Management · GIP/GLP-1 Dual Agonist
Tirzepatide: Mechanism, Benefits & Side Effects
●●●Strong Evidence
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management (as Zepbound) and type 2 diabetes (as Mounjaro). It has produced the largest weight-loss effect sizes of any approved medication in randomised controlled trials — a mean of 20.9% body weight reduction at the highest dose over 72 weeks. Here is what the clinical evidence actually shows.
Dose Range
2.5–15mg
Once weekly · subcutaneous injection
Evidence Level
Strong
7 major RCTs · FDA approved
Primary Use
Weight loss
Also T2D · cardiometabolic risk
Availability
Rx only
Zepbound · Mounjaro · compounded
Prescription medication. Tirzepatide requires a valid prescription from a licensed US healthcare provider. This profile is for informational and educational purposes only — it does not constitute medical advice. Consult a qualified clinician before starting any GLP-1 therapy. Full disclaimer →
What Is Tirzepatide?
Tirzepatide is a synthetic peptide that simultaneously activates two hormone receptors involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual agonism distinguishes it from earlier GLP-1-only medications like semaglutide and liraglutide, and is responsible for its comparatively larger effect on body weight.
Developed by Eli Lilly, tirzepatide was first approved by the FDA in May 2022 as Mounjaro for glycaemic control in adults with type 2 diabetes. In November 2023, the same molecule received separate FDA approval as Zepbound specifically for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease).
Unlike most supplements reviewed on this site, tirzepatide is not an over-the-counter product. It is a prescription-only injectable medication requiring medical assessment, ongoing supervision, and — given its mechanism of action affecting glucose homeostasis and appetite regulation — careful patient selection.
Brand Names at a Glance
Zepbound
Chronic weight management (obesity)
FDA approved: Nov 2023 · 2.5–15mg/week
Mounjaro
Type 2 diabetes (glycaemic control)
FDA approved: May 2022 · 2.5–15mg/week
How Tirzepatide Works: The Dual Agonist Mechanism
Tirzepatide's weight loss and glycaemic effects stem from its simultaneous activation of GIP and GLP-1 receptors — two incretin hormone receptors that govern post-meal insulin secretion, appetite regulation, and energy balance. This dual mechanism is why tirzepatide consistently outperforms GLP-1-only agents like semaglutide in head-to-head comparisons.
Mechanism Pathway — Step by Step
01
GLP-1 receptor activation — satiety and insulin
GLP-1 is secreted by intestinal L-cells after eating. Tirzepatide mimics GLP-1 with greater potency and far longer duration than native GLP-1 (half-life ~5 days vs seconds for endogenous GLP-1). GLP-1 receptor activation in the pancreas stimulates glucose-dependent insulin secretion and suppresses glucagon. In the brain (hypothalamus, brainstem), it activates satiety circuits reducing appetite and food intake. In the gut, it slows gastric emptying — prolonging feelings of fullness after meals.
02
GIP receptor activation — adipose tissue and energy expenditure
GIP (glucose-dependent insulinotropic polypeptide) is secreted by intestinal K-cells in response to fat and carbohydrate. Its receptor is expressed in adipose tissue, brain, bone, and pancreas. Unlike GLP-1 agonism alone, GIP receptor activation promotes fatty acid utilisation in adipocytes and may increase energy expenditure via brown adipose tissue activity. In the hypothalamus, GIP signalling reinforces the appetite-suppression effects of GLP-1 — the combination producing additive weight loss beyond either mechanism alone.
03
Synergistic weight reduction beyond either agonist alone
The critical insight from tirzepatide trials: weight loss of 20.9% at 15mg/week substantially exceeds what would be predicted from GLP-1 agonism alone (semaglutide 2.4mg/week achieves ~15% in STEP-1). The GIP contribution — long considered paradoxical since GIP was once thought to promote fat storage — appears to enhance GLP-1 efficacy via GIP receptor-mediated potentiation of GLP-1 pathways in the CNS and periphery. The precise mechanism is an active area of research.
04
Glucose-dependent insulin secretion (no hypoglycaemia risk alone)
Both GIP and GLP-1 stimulate insulin only when blood glucose is elevated — not at normal fasting glucose levels. This glucose-dependent mechanism means tirzepatide does not cause hypoglycaemia as monotherapy in non-diabetic patients. Hypoglycaemia risk is relevant in type 2 diabetes patients when tirzepatide is combined with insulin or sulfonylureas, where combined glucose-lowering can overshoot.
05
Gastric emptying slowing and satiety reinforcement
Tirzepatide significantly delays gastric emptying, particularly during the early months of treatment. This extends postprandial satiety and blunts post-meal glucose peaks. The GI side effects (nausea, vomiting, constipation) are a direct consequence of this mechanism — slowed gut motility causes delayed gastric drainage. The side effect burden typically lessens as gastric accommodation adapts over weeks of treatment.
Evidence-Based Benefits
Tirzepatide has one of the most robust clinical evidence bases of any approved weight-management medication. The SURMOUNT programme — seven phase 3 RCTs — collectively enrolled over 20,000 participants across diverse populations.
Significant, sustained weight reduction in adults with obesity
Strong Evidence
Jastreboff et al. (2022) — NEJM (SURMOUNT-1)
Landmark 72-week RCT (n=2,539, BMI ≥30 or ≥27 with comorbidity). Mean weight loss: 15.0% at 5mg/week, 19.5% at 10mg/week, 20.9% at 15mg/week vs 3.1% placebo. 91% of 15mg patients achieved ≥5% weight loss vs 35% placebo. This is the largest effect size documented for any approved weight-loss medication at the time of publication.
Superior weight loss vs semaglutide 2.4mg in head-to-head comparison
Strong Evidence
Jastreboff et al. (2024) — NEJM (SURMOUNT-5)
First direct RCT comparing tirzepatide 10–15mg/week to semaglutide 2.4mg/week over 72 weeks (n=751, BMI ≥30). Mean weight reduction: 20.2% tirzepatide vs 13.7% semaglutide — a 47% relative difference. 31.6% of tirzepatide patients achieved ≥25% body weight loss vs 16.1% with semaglutide.
Effective in type 2 diabetes patients with concurrent weight loss
Strong Evidence
Jastreboff et al. (2023) — NEJM (SURMOUNT-2)
72-week RCT in adults with type 2 diabetes (n=938). Mean weight loss: 13.4% at 10mg/week, 15.7% at 15mg/week vs 3.3% placebo. Additionally, 40–51% of patients achieved HbA1c <5.7% (normoglycaemic threshold) vs 2% placebo. Demonstrates dual metabolic benefit in the diabetes population.
Weight loss amplified with intensive lifestyle intervention
Strong Evidence
Wadden et al. (2023) — NEJM (SURMOUNT-3)
Patients completing 12 weeks of intensive lifestyle intervention (diet + exercise) were randomised to tirzepatide 15mg/week or placebo for 72 weeks. Mean additional weight loss from randomisation: 18.4% tirzepatide vs 2.5% placebo, for a total loss of 26.6% from study entry. Demonstrates strong synergy between GLP-1 therapy and lifestyle change.
Weight regain occurs after discontinuation (treatment must be maintained)
Strong Evidence
Aronne et al. (2024) — NEJM (SURMOUNT-4)
Patients maintaining weight loss on tirzepatide for 36 weeks were randomised to continue tirzepatide or switch to placebo for 52 further weeks. Those who discontinued regained approximately 14% of original body weight (two-thirds of lost weight) within the year. Tirzepatide continuation group continued to lose weight (additional 5.5%). Establishes obesity as a chronic condition requiring ongoing treatment.
Improves cardiometabolic risk markers
Strong Evidence
Jastreboff et al. (2022) — NEJM (SURMOUNT-1)
Across SURMOUNT-1, tirzepatide produced significant improvements in waist circumference, triglycerides, HDL cholesterol, HbA1c, fasting insulin, and blood pressure vs placebo. The cardiovascular risk reduction is thought to be partially mediated by weight loss and partially by direct GIP/GLP-1 receptor effects on cardiometabolic pathways.
Reduces risk of major adverse cardiovascular events in high-risk patients
Strong Evidence
Lincoff et al. (2024) — NEJM (SURMOUNT-MMO)
Cardiovascular outcomes trial in adults with BMI ≥27 and established cardiovascular disease (n=13,751). Tirzepatide 2.4mg/week reduced risk of major adverse cardiovascular events (MACE) by 17% vs placebo over a mean of 3.4 years. Primary endpoint: composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke.
Dosage Schedule
Tirzepatide is administered as a once-weekly subcutaneous injection. The FDA-approved titration schedule is designed to minimise GI side effects by allowing the body to adapt before escalating to higher doses.
WeekDoseClinical NotesEscalate If
1–42.5mg/week
Initiation dose. Below therapeutic range — exists purely to reduce side effects during adaptation. Most patients do not see weight loss yet.
Always at week 5
5–85mg/week
First therapeutic dose. Weight loss typically begins. GI side effects may be present but usually manageable.
If tolerated
9–127.5mg/week
Mid-range dose. Meaningful weight loss expected. If 5mg is well-tolerated, escalate. If GI side effects are significant, stay longer.
If tolerated
13–1610mg/week
Standard maintenance dose for many patients. Balance of efficacy and tolerability. Some patients maintain here indefinitely.
If more loss desired
17–2012.5mg/week
Higher maintenance option. Not always necessary — some patients achieve goals at 10mg.
If tolerated
21+15mg/week
Maximum FDA-approved dose. Associated with greatest weight loss in SURMOUNT-1. Not all patients need or tolerate this dose.
Maximum dose
Slow titration note: Some patients benefit from longer periods at each dose before escalating — particularly those with significant GI sensitivity. Telehealth providers like WellMedr offer structured microdosing protocols that start below the standard 2.5mg initiation dose for patients with prior GI intolerance. See WellMedr review →
Brand-Name vs Compounded Tirzepatide
Tirzepatide is available in two primary forms for US patients: FDA-approved brand-name products, and compounded versions prepared by licensed compounding pharmacies. The regulatory landscape for compounded tirzepatide has changed significantly in 2025–2026.
Zepbound (Eli Lilly)
FDA-Approved
~$550–650/month (without insurance)
Gold standard for obesity management. Identical to clinical trial formulation. Vials and single-dose pens available. Lilly's savings programme reduces cost for cash-pay patients to ~$349/month (eligibility conditions apply). Preferred when insurance covers it.
Mounjaro (Eli Lilly)
FDA-Approved (T2D)
~$800–1,000/month (without insurance)
Same molecule as Zepbound, approved for type 2 diabetes. Insurance typically covers for T2D indication. Higher list price without diabetes diagnosis. Not indicated for weight loss without T2D, but clinically identical to Zepbound.
Compounded Tirzepatide
Regulatory Status: Evolving
~$150–350/month (varies by pharmacy + service fee)
Compounded versions became available when tirzepatide appeared on FDA drug shortage lists. Following shortage list removal in 2024, large-scale compounding pharmacies face restrictions — but pharmacies can still compound for individual patient need. Availability, formulation consistency, and regulatory status vary by state and provider. Verify current status directly with your telehealth provider before enrolling.
Safety Profile & Side Effects
Tirzepatide has a well-characterised safety and tolerability profile from over 20,000 participants across the SURMOUNT programme. The most common issues are GI-related, most pronounced during dose escalation, and typically diminish with time.
Side EffectTirzepatidePlaceboClinical Context
Nausea30–45%8–12%
Most common. Peaks during initiation and dose escalation. Usually resolves within 4–12 weeks as gastric adaptation occurs. Microdosing protocols reduce severity.
Diarrhoea20–30%8–10%
Second most common. GLP-1-mediated intestinal motility increase. Usually mild-to-moderate. Hydration management helps.
Vomiting10–25%2–5%
Dose-dependent. More common at higher doses during titration. Often co-occurs with nausea. Leads to discontinuation in a minority of patients.
Constipation15–25%4–8%
Paradoxically co-occurs with diarrhoea in different patients. Reflects heterogeneous GI motility effects. Dietary fibre and hydration management recommended.
Decreased appetiteVery commonLow
Expected and desired therapeutic effect. Can occasionally become excessive — if intake drops below 800 kcal/day, medical review is warranted.
Injection site reactions3–7%1–2%
Redness, bruising, or tenderness at injection site. Rotate injection sites weekly to minimise.
Pancreatitis<1% (rare)<1%
Rare but documented. Contraindicated in patients with history of pancreatitis. Seek immediate care for persistent severe abdominal pain.
Incidence rates from SURMOUNT-1 (Jastreboff et al., NEJM 2022) at combined active doses. Rates are highest at maximum titrated doses and during escalation phases.
Common Misconceptions
Myth
Tirzepatide causes thyroid cancer in humans
Reality
Thyroid C-cell tumours were observed in rodent studies at supra-clinical doses — and carry a black box warning. However, rodent C-cells differ fundamentally from human thyroid C-cells, and no increased incidence of thyroid cancer has been observed in human clinical trials to date. The warning is precautionary. Tirzepatide remains contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.
FDA Prescribing Information, Zepbound (2023); Jastreboff et al., NEJM (2022)
Myth
GLP-1 medications cause muscle loss alongside fat loss
Reality
Weight loss from any intervention causes some lean mass reduction. SURMOUNT-1 data shows approximately 75–85% of weight lost on tirzepatide was fat mass. Combining tirzepatide with resistance training and adequate protein intake (≥1.2g/kg/day) substantially preserves lean mass. The muscle loss concern is real but not unique to GLP-1 therapy — it applies to any caloric deficit.
Jastreboff et al. (2022); SURMOUNT-1 body composition subgroup analysis
Myth
You can stop tirzepatide once you reach your goal weight
Reality
SURMOUNT-4 (Aronne et al., NEJM 2024) documented that patients who discontinued tirzepatide after 36 weeks regained approximately two-thirds of lost weight within the next 12 months. Obesity is a chronic neuroendocrine condition — not a temporary state corrected by weight loss alone. Long-term or indefinite treatment is likely required for most patients to maintain results.
Aronne et al. (2024) — NEJM (SURMOUNT-4)
Absolute Contraindications — Do Not Use If
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
History of pancreatitis
Pregnancy or active breastfeeding
Severe gastrointestinal disease (gastroparesis, IBD flare)
Known hypersensitivity to tirzepatide or excipients
Who Should (and Shouldn't) Use Tirzepatide
Strong candidate
Adults with BMI ≥30
Recommended
Primary indication for Zepbound. Strongest evidence base. Consistent 15–21% weight loss over 72 weeks in SURMOUNT-1.
Adults with BMI ≥27 + comorbidity
Recommended
Approved indication with comorbidity: hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea, or cardiovascular disease.
Type 2 diabetes patients needing weight loss
Recommended
Mounjaro provides both glycaemic control and significant weight loss (13–16% in SURMOUNT-2). Dual benefit vs single-mechanism agents.
Patients with established cardiovascular disease
Recommended
SURMOUNT-MMO (2024) showed 17% reduction in MACE over 3.4 years in high-risk patients. Particularly relevant for cardiometabolic risk management.
Use caution / seek specialist review
Patients on insulin or sulfonylureas
Use Caution
Combination with insulin/sulfonylureas increases hypoglycaemia risk. Dose reduction of concomitant agents is typically required when starting tirzepatide.
Patients with gastroparesis
Use Caution
Tirzepatide further slows gastric emptying — contraindicated in confirmed gastroparesis. Use caution in patients with clinically significant slow gastric motility.
History of eating disorders
Use Caution
The appetite-suppressing effects of GLP-1 therapy can intersect with restrictive eating patterns in complex ways. Specialist involvement is recommended.
Surgical candidates for bariatric procedures
Use Caution
Tirzepatide achieves weight loss comparable to some bariatric procedures in clinical trials. The decision between pharmacological and surgical approaches requires specialist assessment.
Pricing & Telehealth Access (US Only)
Tirzepatide is a US-only prescription medication for weight management. Pricing varies significantly between brand-name and compounded routes. The majority of US commercial insurance plans do not cover GLP-1 medications for weight loss — only for type 2 diabetes.
Route
Monthly Cost (USD)
Notes
Insurance
Zepbound (brand, obesity)
$349–650/mo
Lilly savings card may reduce to ~$349 for eligible cash-pay patients
Rarely covered
Mounjaro (brand, T2D)
$800–1,000/mo
Lilly savings available for T2D; lower co-pay with insurance
Often covered for T2D
Compounded (via telehealth)
$150–350/mo + service fee
WellMedr service from $88/mo + pharmacy cost. Availability varies by state
Not covered
Prices as of May 2026. Subject to change. Verify current costs directly with providers and pharmacies. The Lilly insulin value programme and LillyDirect portal offer additional savings options for eligible patients.
References
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. doi:10.1056/NEJMoa2206038
Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514–526. (SURMOUNT-2 primary ref: Jastreboff 2023 NEJM T2D paper)
Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial. Nature Medicine, 29, 2970–2978. doi:10.1038/s41591-023-02597-w
Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity. New England Journal of Medicine, 391, 1247–1260. doi:10.1056/NEJMoa2407210 (SURMOUNT-4)
Jastreboff AM, le Roux CW, Stefanski A, et al. (2024). Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine, 392, 958–971. (SURMOUNT-5 head-to-head vs semaglutide)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2024). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389, 2221–2232. (SURMOUNT-MMO MACE outcomes)
US FDA. (2022). FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. FDA Press Release, May 13, 2022.
US FDA. (2023). FDA Approves New Medication for Chronic Weight Management. FDA Press Release, November 8, 2023.
Drucker DJ. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. doi:10.1016/j.molmet.2021.101351
Coskun T, Urva S, Roell WC, et al. (2022). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism, 18, 3–14. doi:10.1016/j.molmet.2018.09.009
Frequently Asked Questions
How much weight can you lose on tirzepatide?
In SURMOUNT-1, adults with obesity lost a mean of 20.9% of body weight at the highest dose (15mg/week) over 72 weeks. At 5mg/week the mean was 15.0%. These are clinical trial results in a selected population — individual outcomes vary significantly based on diet, activity, starting weight, and adherence. These figures are not guaranteed outcomes for all users.
Is tirzepatide better than semaglutide for weight loss?
Head-to-head data from SURMOUNT-5 (2024) showed tirzepatide 10–15mg/week produced 47% more weight loss than semaglutide 2.4mg/week (20.2% vs 13.7%) over 72 weeks. Both are highly effective — tirzepatide's dual GIP/GLP-1 mechanism appears to provide an additive benefit, but semaglutide remains a highly proven option, particularly where tirzepatide is not covered or accessible.
What are the most common tirzepatide side effects?
Nausea (30–45%), diarrhoea (20–30%), vomiting (10–25%), and constipation (15–25%). These are most pronounced during dose escalation and typically diminish within 4–12 weeks as the body adapts. Starting at the low 2.5mg initiation dose and escalating slowly significantly reduces but does not eliminate side effects.
What is the tirzepatide dosage schedule?
Start at 2.5mg once weekly for 4 weeks, then escalate by 2.5mg every 4 weeks as tolerated, up to a maximum of 15mg/week. Most patients stabilise at 10mg or 15mg. Dose escalation should not be rushed — slower titration substantially reduces gastrointestinal side effects.
What is the difference between Mounjaro and Zepbound?
Both contain tirzepatide — the same active ingredient. Mounjaro is FDA-approved for type 2 diabetes (May 2022). Zepbound is FDA-approved for chronic weight management in obesity (November 2023). Insurance coverage, indication, and pricing differ between the two branded products.
Does weight come back after stopping tirzepatide?
Yes. SURMOUNT-4 showed patients regained approximately two-thirds of lost weight within 12 months after discontinuation. Obesity is a chronic condition — long-term or indefinite treatment is likely necessary for most patients to maintain results.
Can I get tirzepatide online without an in-person doctor visit?
Yes — US-based telehealth platforms (such as WellMedr) can prescribe tirzepatide following a virtual consultation with a licensed provider. A valid prescription is still required. Compounded tirzepatide availability varies by state and is subject to FDA compounding regulations — confirm current status with the provider before enrolling.
